

# 2nd HKU International Musculoskeletal Tumour Course

**Date:** 7 December 2018

**Venue:** Room 1420, Research, Education and Administration Block,  
The University of Hong Kong-Shenzhen Hospital, 1, Haiyuan  
1st Road, Futian District, Shenzhen, Guangdong, China

**Date:** 8-9 December 2018

**Venue:** Seminar Rooms 1-3, G/F, Laboratory Block,  
21 Sassoon Road, Pokfulam, Hong Kong



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA



香港大学深圳医院  
The University of Hong Kong - Shenzhen Hospital



# **XGEVA® is now indicated for treatment of Giant Cell Tumor of Bone (GCTB)**

**For treatment of adults and skeletally mature adolescents with GCTB that is unresectable or where surgical resection is likely to result in severe morbidity**



**72% of Patients Achieve Tumor Response\*<sup>2</sup>**



**Delays & Reduces Scope of Surgery<sup>1</sup>**



**Reduces Bone Pain<sup>1</sup>**



**Well-established Safety Profile<sup>1</sup>**

\*Defined as a partial or complete response by any criteria.

## References:

1. XGEVA® Approved Hong Kong Prescribing Information Jun 2016 2. Chawlas S, et al. Lancet Oncol. 2013;14(9):901-908

## XGEVA® (denosumab) Abbreviated Prescribing Information

XGEVA® (denosumab) Solution for Injection 120 mg

**INDICATIONS** Indicated for prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours, and treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. **DOSAGE AND ADMINISTRATION** Supplementation of at least 500 mg calcium and 400 IU vitamin D daily is required in all patients, unless hypercalcaemia is present. Prevention of skeletal related events in adults with bone metastases from solid tumours: The recommended dose is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm. **Giant cell tumour of bone:** The recommended dose of XGEVA is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm with additional 120 mg doses on days 8 and 15 of treatment of the first month of therapy. **Patients with renal impairment:** No dose adjustment is required in patients with renal impairment. **Patients with hepatic impairment:** The safety and efficacy of denosumab have not been studied in patients with hepatic impairment. **Elderly patients (age ≥ 65):** No dose adjustment is required in elderly patients. **Paediatric population:** XGEVA is not recommended in paediatric patients (age < 18) other than skeletally mature adolescents with giant cell tumour of bone. **CONTRAINDICATIONS** Contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, and in patients with severe, untreated hypocalcaemia. Contraindicated in patients with unhealed lesions from dental or oral surgery. **SPECIAL WARNINGS AND PRECAUTIONS FOR USE** **Calcium and Vitamin D supplementation:** Supplementation with calcium and vitamin D is required in all patients unless hypercalcaemia is present. Hypocalcaemia: Pre-existing hypocalcaemia must be corrected prior to initiating therapy with XGEVA. Hypocalcaemia can occur at any time during therapy with XGEVA. **Renal impairment:** Patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis are at greater risk of developing hypocalcaemia. **Osteonecrosis of the jaw (ONJ):** ONJ has been reported in patients receiving XGEVA. The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth. A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with XGEVA in patients with concomitant risk factors. Atypical fractures of the femur: Atypical femoral fractures have been reported in patients receiving XGEVA. Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal regions of the femur. Patients with growing skeletons: XGEVA is not recommended in patients with growing skeletons. Clinically significant hypercalcaemia has been reported in XGEVA-treated patients with growing skeletons weeks to months following treatment discontinuation. **Others:** Patients being treated with XGEVA should not be treated concomitantly with other denosumab containing medicinal products, or with bisphosphonates. **INTERACTIONS** No interaction studies have been performed. **PREGNANCY, LACTATION AND FERTILITY** **Pregnancy:** There are no adequate data from the use of XGEVA in pregnant women. XGEVA is not recommended for use in pregnant women and women of childbearing potential not using highly effective contraception. **Breast-feeding:** It is unknown whether denosumab is excreted in human milk. **Fertility:** No data are available on the effect of denosumab on human fertility. **UNDESIRABLE EFFECTS** Hypocalcaemia has commonly been reported following XGEVA administration, mostly within the first 2 weeks. The most common adverse reactions with XGEVA are musculoskeletal pain. The adverse reactions identified in clinical trials and from post-marketing experience: Very common (≥ 1/10) adverse reactions include: dyspnoea, diarrhoea and musculoskeletal pain. Common (≥ 1/100 to < 1/10) adverse reactions include: hypocalcaemia, hypophosphataemia, tooth extraction, hyperhidrosis and osteonecrosis of the jaw. **OVERDOSE** There is no experience with overdose in clinical studies.

Abbreviated Prescribing Information Version: HKP/20160002  
Please read the full prescribing information prior to administration and full prescribing information is available on request.  
XGEVA® is a registered trademark owned or licensed by Amgen Inc., its subsidiaries, or affiliates.

# Contents

Welcome Message	2
Organizing Committee	6
Overseas and Regional Speakers	7
Local Speakers	8
Moderators	9
Programme	10
Accreditations	15
Acknowledgements	16

# 2nd HKU International Musculoskeletal Tumour Course

## Welcome Message




### **Professor Kenneth MC Cheung**

Jessie Ho Professor in Spine Surgery  
Chair Professor and Head  
Department of Orthopaedics and Traumatology  
The University of Hong Kong

Welcome to the 2nd HKU International Musculoskeletal Tumour Course!

Following on from the success of the inaugural event last year, we continue this year with the aim of promoting knowledge about musculoskeletal oncology across the region. I would like to extend a warm welcome to our all-star faculty whom are renowned both regionally and internationally. Together with local experts, they will provide you with the most up-to-date knowledge across multiple specialties involved in musculoskeletal oncology.





Uniquely, the course this year will span across the border into China with the first day taking place at The University of Hong Kong-Shenzhen Hospital. We hope this will facilitate participants from both regions and help to foster communication and collaboration in the future.

I would like to express my thanks to the faculty for their support and for sharing their expertise, and to our generous sponsors whom make this course possible.

Wish you a rewarding and enjoyable weekend!

# 2nd HKU International Musculoskeletal Tumour Course

## Welcome Message

### Course Directors



**Dr. Ying-lee Lam**

Consultant  
Department of Orthopaedics and  
Traumatology  
Queen Mary Hospital

On behalf of the organizing committee, I am delighted to welcome you to the "The Second HKU International Musculoskeletal Tumour Course". This unique course provides a platform to learn and review the basics of orthopaedic tumour surgery, to exchange views and to share experiences with our overseas professors, colleagues and friends. For most of us, this growing subspecialty has become a challenge. For those who are interested in orthopaedic tumour surgery, this course will be a chance to gain a more comprehensive understanding of the topics. Therefore, we would like to welcome you onto the course and we very much look forward to your enthusiastic participation.




**Professor Pietro Ruggieri**

Professor  
Department of Orthopaedic  
Oncology  
University of Padova, Italy

Dear Friends!

It gives me great pleasure, along with Dr. Albert Lam Director of the Course, to welcome every single one of you to the Second HKU International Musculoskeletal Tumour Course to be held from the 7-9 December 2018.



I am particularly thrilled to present this Course, which follows the first edition of 2017, since it is under the auspices of University of Padova, and it is joint to our Musculoskeletal Oncology Course in Italy.

First of all, I want to wholeheartedly thank two dear friends, Prof. Kenneth Cheung and Dr. Albert Lam, respectively, Head and Tumour Division Chief at the Department of Orthopaedics and Traumatology.

The Department of Orthopaedics and Traumatology in Hong Kong has a long tradition of orthopaedic surgery, and primarily vertebral one, starting with Prof. A. R. Hodgson. This valuable tradition has been renewed with increasing success until today, and it is well represented here by the Head, Prof. Kenneth Cheung. Indeed, the Department has increasingly distinguished itself in orthopedic oncology as well, reaching today very high levels.

This year, the Course takes place in Hong Kong and China. In my view, this is a noteworthy sign of internationalization and spread of orthopedic oncology in the most populous nation in the world. However, this is a Course by its nature international, and our wish is that many participants can benefit of it.

Last but not least: let me conclude saying that the honor of being involved in this Course, is enriched by the pleasure of meeting again two close friends, as with such friends it is more and more stimulating to embark on a journey or adventure!

# 2nd HKU International Musculoskeletal Tumour Course

## Organizing Committee

### Course Directors

Dr Ying-lee Lam (O&T, QMH)

Professor Pietro Ruggieri (University of Padova, Italy)

### Members

Dr. Calvin Chiu (O&T, PWH)

Dr. Benjamin Fong (O&T, QEH)

Dr. Zusheng He (O&T, HKU Shenzhen Hospital)

Dr. Wai-yip Ho (O&T, QMH)

Dr. Defu Liu (O&T, HKU Shenzhen Hospital)

Dr. Michelle Luk (O&T, QMH)

Dr. Ma Felma Rayel (Bicol Medical Centre, Philippines)

Dr. Tak-man Wong (O&T, HKU)

Dr. Raymond Yau (O&T, QMH)

### Secretarial Support

Ms Daisy Peng (O&T, HKU Shenzhen Hospital)

Ms Jenny Tam (O&T, HKU)



## Overseas and Regional Speakers

**Wei Ming Chen**

**Orthopaedic Professor and Vice Dean**

School of Medicine

National Yang-Ming University, Taiwan

**Vice Superintendent**

Taipei Veterans General Hospital, Taiwan

**G. Douglas Letson**

**Professor**

Department of Orthopaedic Oncology

Moffitt Cancer Center, University of South Florida, USA

**Xiao Hui Niu**

**Chair and Professor**

Department of Orthopaedic Oncology

Beijing Ji Shui Tan Hospital, Peking University, China

**Pietro Ruggieri**

**Professor**

Department of Orthopaedic Oncology

University of Padova, Italy

**Hiroyuki Tsuchiya**

**Professor**

Department of Orthopaedic Surgery

Kanazawa University, Japan

**Jin Wang**

**Chair Professor**

Department of Musculoskeletal Oncology

Sun Yat Sen University Cancer Center, China

# 2nd HKU International Musculoskeletal Tumour Course

## Local Speakers

**Alexander Chan**

**Chief of Service**

Department of Pathology  
Queen Elizabeth Hospital

**Benjamin Fong**

**Consultant**

Department of Orthopaedics & Traumatology  
Queen Elizabeth Hospital

**Gerry Kwok**

**Resident Specialist**

Department of Medicine  
Queen Mary Hospital

**Ying Lee Lam**

**Consultant**

Department of Orthopaedics & Traumatology  
Queen Mary Hospital

**Vince Lau**

**Associate Consultant**

Department of Radiology  
Queen Mary Hospital

**Victor Lee**

**Clinical Associate Professor**

Department of Clinical Oncology  
The University of Hong Kong

**Roger Ngan**

**Clinical Professor**

Department of Clinical Oncology  
The University of Hong Kong

**Tony Shek**

**Consultant Pathologist**

Department of Anatomical Pathology  
Queen Mary Hospital

# Moderators

**Calvin Chiu**

**Associate Consultant**

Department of Orthopaedics & Traumatology  
Prince of Wales Hospital

**Benjamin Fong**

**Consultant**

Department of Orthopaedics & Traumatology  
Queen Elizabeth Hospital

**Wai Yip Ho**

**Associate Consultant**

Department of Orthopaedics & Traumatology  
Queen Mary Hospital

**Tony Shek**

**Consultant Pathologist**

Department of Anatomical Pathology  
Queen Mary Hospital

**Tak Man Wong**

**Clinical Assistant Professor**

Department of Orthopaedics & Traumatology  
The University of Hong Kong

**Raymond Yau**

**Associate Consultant**

Department of Orthopaedics & Traumatology  
Queen Mary Hospital



# 2nd HKU International Musculoskeletal Tumour Course

## Programme (Day 1)

### 7 December 2018 (Friday) Principles of Musculoskeletal Tumour Surgery (D1 at HKUSZ Hospital, Shenzhen)

Time	Topic	Speaker
08:00 - 08:50	<b>Registration / Check-in</b>	
08:50 - 09:00	Opening Speech	Prof. Kenneth Cheung & Prof. Pietro Ruggieri
	<i>Moderators: Dr. Tony Shek &amp; Dr. Tak Man Wong</i>	
09:00 - 09:30	Principles of bone tumour pathology	Dr. Alexander Chan
09:30 - 10:00	Principles of bone tumour imaging	Prof. Douglas Letson
10:00 - 10:10	Q&A	
10:10 - 10:30	Coffee Break	
10:30 - 11:00	Principles of soft tissue tumours pathology	Dr. Tony Shek
11:00 - 11:30	Imaging of soft tissue tumours	Prof. Douglas Letson
11:30 - 12:30	Case presentation (1) and discussion: ask the participants/ experts	Dr. Zusheng He & Dr. Defu Liu
12:30 - 12:45	Q&A	
12:45 - 14:00	Lunch Break	
14:00 - 14:30	Biopsy techniques	Prof. Wei Ming Chen
14:30 - 15:00	Surgical margins	Prof. Jin Wang
15:00 - 15:30	"No Touch lesion"	Prof. Pietro Ruggieri
15:30 - 16:00	Coffee break	

16:00 - 17:00 Case presentation (2) and discussion: ask the participants/experts

Dr. Zusheng He &  
Dr. Defu Liu

17:00 - 17:15 Q&A

17:15 Adjourn

17:15 - 18:00 Group Photo & HKUSZ Hospital Tour

18:00 - 20:00 Welcome Dinner for Speakers & Participants  
(Optional)

**End of Day 1**


# 2nd HKU International Musculoskeletal Tumour Course

## Programme (Day 2)

**8 December 2018 (Saturday)**  
**Principles of Bone Tumour Surgery**  
**(D2 at HKU LKS Faculty of Medicine Bldg)**

Time	Topic	Speaker
08:00 - 08:50	<b>Registration / Check-in</b>	
08:50 - 09:00	Welcoming Speech	Dr. Ying Lee Lam
	<i>Moderators: Dr. Benjamin Fong &amp; Dr. Wai Yip Ho</i>	
09:00 - 09:30	Prosthetic bone reconstruction: implant design and long term outcome	Prof. Xiao Hui Niu
09:30 - 10:00	Biological bone reconstruction: techniques and long term outcome	Prof. Hiroyuki Tsuchiya
10:00 - 10:30	Local destruction of bone lesion	Prof. Wei Ming Chen
10:30 - 10:40	Q&A	
10:40 - 11:00	Coffee Break	
11:00 - 11:30	Management of osteosarcoma	Prof. Pietro Ruggieri
11:30 - 12:00	Management of giant cell tumour of bone	Prof. Jin Wang
12:00 - 12:30	Management of chondroid lesion in XR and chondrosarcoma	Prof. Pietro Ruggieri
12:30 - 12:40	Q&A	
12:40 - 14:00	Group Photo & Lunch Break	
14:00 - 14:30	Pelvic tumour: surgical management	Prof. Xiao Hui Niu
14:30 - 15:00	Management of bone metastasis: the principles	Prof. Hiroyuki Tsuchiya





15:00 - 16:00	Case presentation (3) and discussion: ask the participants/ experts	Dr. Michelle Luk
16:00 - 16:30	Coffee Break	
16:30 - 17:00	Radiotherapy and chemotherapy in primary orthopaedic bone tumour	Dr. Victor Lee
17:00 - 17:30	Interventional radiology in orthopaedic tumour surgery	Dr. Vince Lau
17:30 - 18:00	Case presentation (4) and discussion: ask the participants/experts	Dr. Michelle Luk
18:00 - 18:10	Q&A	
18:10	Adjourn	

**End of Day 2**

# 2nd HKU International Musculoskeletal Tumour Course

## Programme (Day 3)

**9 December 2018 (Sunday)**  
**Principles of Soft Tissue Tumour Surgery**  
**(D3 at HKU LKS Faculty of Medicine Bldg)**

Time	Topic	Speaker
08:00-09:00	Registration / Check-in	
	<i>Moderators: Dr. Calvin Chiu &amp; Dr. Raymond Yau</i>	
09:00-09:30	Management of soft tissue tumours: the principles	Dr. Benjamin Fong
09:30-10:00	Techniques of plastic surgery in musculoskeletal tumour surgery	Dr. Ying Lee Lam
10:00-10:30	Personalized medical treatment in soft tissue sarcoma	Dr. Gerry Kwok
10:30-11:00	Radiotherapy for soft tissue sarcomas: from principles to state of the art practice	Prof. Roger Ngan
11:00-11:30	Coffee Break	
11:30-12:00	Radiation induced sarcoma	Prof. Douglas Letson
12:00-13:00	Case presentation (5) and discussion: ask the participants/experts	Dr. Ma Felma Rayel
13:00-13:10	Q&A	
13:10	Closing Remarks	Dr. Ying Lee Lam

**End of Day 3**

## Accreditations

College / Association	Credit Points Awarded			
	Day 1 (7/12/18)	Day 2 (8/12/18)	Day 3 (9/12/18)	Whole Function
<b>The Hong Kong College of Orthopaedic Surgeons</b>	5 Cat A / 2 Rehab / 5 Training Points	5 Cat A / 2 Rehab / 5 Training Points	3 Cat A / 1 Rehab / 3 Training Points	N/A
<b>Hong Kong College of Radiologists</b>	6.5 (Cat A)	6.5 (Cat A)	3.5 (Cat A)	N/A
<b>The Hong Kong College of Pathologists</b>	4 (Cat PP)	4 (Cat PP)	3 (Cat PP)	N/A
<b>The Hong Kong College of Family Physicians</b>	5 (Cat 5.2)	5 (Cat 5.2)	3 (Cat 5.2)	Max. 10 (Cat 5.2)
<b>The College of Surgeons of Hong Kong</b>	6	6	3.5	N/A
<b>HKWC CNE / PEM Accreditation Panel</b>	Pending for approval			



# 2nd HKU International Musculoskeletal Tumour Course

## Acknowledgements

**AMGEN<sup>®</sup>**





**BRAINLAB**

**stryker**

# NAVIGATION. UPDATED.

WITH BRAINLAB SPINAL NAVIGATION AND AIRO.

UNEXPECTED SETUP VERSATILITY  
UNINTERRUPTED IMAGE REGISTRATION  
UNOBSTRUCTED SPINAL VIEWS



**Co-organized by**

**Department of Orthopaedics and Traumatology, The University of Hong Kong**

**Department of Orthopaedics and Traumatology, HKU Shenzhen Hospital**

**and**

**Department of Orthopaedic Oncology, University of Padova, Italy**